학술논문
'학술논문'
에서 검색결과 8,538건 | 목록
1~20
Conference
2024 9th International Conference on Applying New Technology in Green Buildings (ATiGB) Applying New Technology in Green Buildings (ATiGB), 2024 9th International Conference on. :57-61 Aug, 2024
Report
A Single-Center Observational Study on the Impact of Symptom Assessment Timing on the Short-Term Efficacy of 5-ASA Therapy in Patients With Initial-Onset or Relapsed Mild-to-Moderate Active Ulcerative Colitis
Bressler B, Marshall JK, Bernstein CN, Bitton A, Jones J, Leontiadis GI, Panaccione R, Steinhart AH, Tse F, Feagan B; Toronto Ulcerative Colitis Consensus Group. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology. 2015 May;148(5):1035-1058.e3. doi: 10.1053/j.gastro.2015.03.001. Epub 2015 Mar 4.
Orchard TR, van der Geest SA, Travis SP. Randomised clinical trial: early assessment after 2 weeks of high-dose mesalazine for moderately active ulcerative colitis - new light on a familiar question. Aliment Pharmacol Ther. 2011 May;33(9):1028-35. doi: 10.1111/j.1365-2036.2011.04620.x. Epub 2011 Mar 8.
Hanauer SB, Sandborn WJ, Kornbluth A, Katz S, Safdi M, Woogen S, Regalli G, Yeh C, Smith-Hall N, Ajayi F. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005 Nov;100(11):2478-85. doi: 10.1111/j.1572-0241.2005.00248.x.
Pruitt R, Hanson J, Safdi M, Wruble L, Hardi R, Johanson J, Koval G, Riff D, Winston B, Cross A, Doty P, Johnson LK. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. Am J Gastroenterol. 2002 Dec;97(12):3078-86. doi: 10.1111/j.1572-0241.2002.07103.x.
Levine DS, Riff DS, Pruitt R, Wruble L, Koval G, Sales D, Bell JK, Johnson LK. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol. 2002 Jun;97(6):1398-407. doi: 10.1111/j.1572-0241.2002.05781.x.
Xu L, He B, Sun Y, Li J, Shen P, Hu L, Liu G, Wang J, Duan L, Zhan S, Wang S. Incidence of Inflammatory Bowel Disease in Urban China: A Nationwide Population-based Study. Clin Gastroenterol Hepatol. 2023 Dec;21(13):3379-3386.e29. doi: 10.1016/j.cgh.2023.08.013. Epub 2023 Sep 1.
Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007 May 12;369(9573):1627-40. doi: 10.1016/S0140-6736(07)60750-8.
Bressler B, Marshall JK, Bernstein CN, Bitton A, Jones J, Leontiadis GI, Panaccione R, Steinhart AH, Tse F, Feagan B; Toronto Ulcerative Colitis Consensus Group. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology. 2015 May;148(5):1035-1058.e3. doi: 10.1053/j.gastro.2015.03.001. Epub 2015 Mar 4.
Orchard TR, van der Geest SA, Travis SP. Randomised clinical trial: early assessment after 2 weeks of high-dose mesalazine for moderately active ulcerative colitis - new light on a familiar question. Aliment Pharmacol Ther. 2011 May;33(9):1028-35. doi: 10.1111/j.1365-2036.2011.04620.x. Epub 2011 Mar 8.
Hanauer SB, Sandborn WJ, Kornbluth A, Katz S, Safdi M, Woogen S, Regalli G, Yeh C, Smith-Hall N, Ajayi F. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005 Nov;100(11):2478-85. doi: 10.1111/j.1572-0241.2005.00248.x.
Pruitt R, Hanson J, Safdi M, Wruble L, Hardi R, Johanson J, Koval G, Riff D, Winston B, Cross A, Doty P, Johnson LK. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. Am J Gastroenterol. 2002 Dec;97(12):3078-86. doi: 10.1111/j.1572-0241.2002.07103.x.
Levine DS, Riff DS, Pruitt R, Wruble L, Koval G, Sales D, Bell JK, Johnson LK. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol. 2002 Jun;97(6):1398-407. doi: 10.1111/j.1572-0241.2002.05781.x.
Xu L, He B, Sun Y, Li J, Shen P, Hu L, Liu G, Wang J, Duan L, Zhan S, Wang S. Incidence of Inflammatory Bowel Disease in Urban China: A Nationwide Population-based Study. Clin Gastroenterol Hepatol. 2023 Dec;21(13):3379-3386.e29. doi: 10.1016/j.cgh.2023.08.013. Epub 2023 Sep 1.
Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007 May 12;369(9573):1627-40. doi: 10.1016/S0140-6736(07)60750-8.
Report
Optimizing IBD Management: A Comparative Study on the Efficacy and Safety of 5-ASA De-escalation in Patients With Ulcerative Colitis and Crohn's Disease on Stable Biologic or Immunomodulator Therapy
Seo J, Kim S, Hong SW, Hwang SW, Park SH, Yang DH, Byeon JS, Myung SJ, Yang SK, Kim YJ, Ye BD. Continuing or stopping 5-aminosalicylates in patients with inflammatory bowel disease on anti-TNF therapy: A nationwide population-based study. Aliment Pharmacol Ther. 2024 Aug;60(3):389-400. doi: 10.1111/apt.18102. Epub 2024 Jun 12.
Chapman TP, Frias Gomes C, Louis E, Colombel JF, Satsangi J. Review article: withdrawal of 5-aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther. 2020 Jul;52(1):73-84. doi: 10.1111/apt.15771. Epub 2020 May 26.
Singh S, Kim J, Zhu W, Dulai PS, Sandborn WJ, Jairath V. No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy. Aliment Pharmacol Ther. 2020 Aug;52(3):481-491. doi: 10.1111/apt.15876. Epub 2020 Jun 23.
Ungaro RC, Limketkai BN, Jensen CB, Yzet C, Allin KH, Agrawal M, Ullman T, Burisch J, Jess T, Colombel JF. Stopping Mesalamine Therapy in Patients With Crohn's Disease Starting Biologic Therapy Does Not Increase Risk of Adverse Outcomes. Clin Gastroenterol Hepatol. 2020 May;18(5):1152-1160.e1. doi: 10.1016/j.cgh.2019.08.012. Epub 2019 Aug 13.
Ungaro RC, Limketkai BN, Jensen CB, Allin KH, Agrawal M, Ullman T, Colombel JF, Jess T. Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts. Gut. 2019 Jun;68(6):977-984. doi: 10.1136/gutjnl-2018-317021. Epub 2018 Nov 12.
Bernstein CN, Tenakoon A, Singh H, Targownik LE. Continued 5ASA use after initiation of anti-TNF or immunomodulator confers no benefit in IBD: a population-based study. Aliment Pharmacol Ther. 2021 Sep;54(6):814-832. doi: 10.1111/apt.16518. Epub 2021 Jul 11.
Seo J, Kim S, Hong SW, Hwang SW, Park SH, Yang DH, Byeon JS, Myung SJ, Yang SK, Kim YJ, Ye BD. Continuing or stopping 5-aminosalicylates in patients with inflammatory bowel disease on anti-TNF therapy: A nationwide population-based study. Aliment Pharmacol Ther. 2024 Aug;60(3):389-400. doi: 10.1111/apt.18102. Epub 2024 Jun 12.
Chapman TP, Frias Gomes C, Louis E, Colombel JF, Satsangi J. Review article: withdrawal of 5-aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther. 2020 Jul;52(1):73-84. doi: 10.1111/apt.15771. Epub 2020 May 26.
Singh S, Kim J, Zhu W, Dulai PS, Sandborn WJ, Jairath V. No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy. Aliment Pharmacol Ther. 2020 Aug;52(3):481-491. doi: 10.1111/apt.15876. Epub 2020 Jun 23.
Ungaro RC, Limketkai BN, Jensen CB, Yzet C, Allin KH, Agrawal M, Ullman T, Burisch J, Jess T, Colombel JF. Stopping Mesalamine Therapy in Patients With Crohn's Disease Starting Biologic Therapy Does Not Increase Risk of Adverse Outcomes. Clin Gastroenterol Hepatol. 2020 May;18(5):1152-1160.e1. doi: 10.1016/j.cgh.2019.08.012. Epub 2019 Aug 13.
Ungaro RC, Limketkai BN, Jensen CB, Allin KH, Agrawal M, Ullman T, Colombel JF, Jess T. Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts. Gut. 2019 Jun;68(6):977-984. doi: 10.1136/gutjnl-2018-317021. Epub 2018 Nov 12.
Bernstein CN, Tenakoon A, Singh H, Targownik LE. Continued 5ASA use after initiation of anti-TNF or immunomodulator confers no benefit in IBD: a population-based study. Aliment Pharmacol Ther. 2021 Sep;54(6):814-832. doi: 10.1111/apt.16518. Epub 2021 Jul 11.
Academic Journal
Tao, Yunjing ; Ren, Huijuan ; Chen, Weilin ; Gao, Ya ; Liu, Sheng ; Sheng, Kangliang ; Wang, Yongzhong
In Food Bioscience July 2025 69
Academic Journal
Snyder, Katherine Brooke; Dalton, Cody; Gershner, Grant; Schlegel, Camille; Massahi, Aslan; Calkins, Chase L.; Eckert, Jeffrey; Berry, William; Hunter, Catherine J.
Academic Journal
Dang, Yan ; Xu, Xinyi ; Ma, Jiuyue ; Zhou, Minsi ; Xu, Chenyue ; Huang, Xueping ; Xu, Fang ; Wang, Zhan ; Shi, Haiyun ; Zhang, Shutian
In iScience 20 June 2025 28(6)
Academic Journal
Academic Journal
Sun, Rongjiao; Zhu, Limei; You, Xianzhu; Chen, Rong; Li, Jiante; Pan, Rongrong; Jin, Yueqi; Zhou, Hua; Tan, Ying; Dong, Jiajia; Hu, Wanle
Academic Journal
Lopes, Sílvio André ; Cardoso, Vinicius Martinho Borges ; Roque-Borda, Cesar Augusto ; Chorilli, Marlus ; Meneguin, Andréia Bagliotti
In International Journal of Biological Macromolecules February 2025 291
Academic Journal
Tursi, Antonio; D'Avino, Alessandro; Brandimarte, Giovanni; Mocci, Giammarco; Pellegrino, Raffaele; Savarino, Edoardo Vincenzo; Gravina, Antonietta Gerarda
Academic Journal
Adamowicz, Monika; Abramczyk, Joanna; Kilanczyk, Ewa; Milkiewicz, Piotr; Łaba, Alicja; Milkiewicz, Malgorzata; Kempinska-Podhorodecka, Agnieszka
Journal of Physiology and Biochemistry: Official Journal of the University of Navarra, Spain. 80(3):573-583
Academic Journal
Academic Journal
Sardou, Hossein Shahdadi ; Sadeghi, Fatemeh ; Garekani, Hadi Afrasiabi ; Akhgari, Abbas ; Hossein Jafarian, Amir ; Abbaspour, Mohammadreza ; Nokhodchi, Ali
In International Journal of Pharmaceutics 10 June 2023 640
Academic Journal
Academic Journal
山西医科大学学报 / Journal of Shanxi Medical University. 56(2):151-157
Academic Journal
ChAracterizing the Remission Status in Patients With Ulcerative Colitis Treated by 5-ASA (CARUC-ASA)
Report
ChAracterizing the Remission Status in Patients With Ulcerative Colitis Treated by 5-ASA
Academic Journal
Qiu, Lei; Shen, Renbin; Wei, Lei; Xu, Shujuan; Xia, Wei; Hou, Yan; Cui, Jinxin; Qu, Rong; Luo, Jiale; Cao, Jian; Yang, Jie; Sun, Jing; Ma, Ronglin; Yu, Qiang
Journal of Nanobiotechnology. 21(1)
Academic Journal
Li, Ping; Luo, Jun; Jiang, Yiming; Pan, Xiaoyi; Dong, Minlei; Chen, Binxin; Wang, Jinhai; Zhou, Hui; Jiang, Huidi; Duan, Yangri; Lin, Nengming
Academic Journal
검색 결과 제한하기
제한된 항목
[검색어] 5-ASA
발행연도 제한
-
학술DB(Database Provider)
저널명(출판물, Title)
출판사(Publisher)
자료유형(Source Type)
주제어
언어